Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupPlasma cell neoplasmsDiseaseMultiple MyelomaSubgroupICD10C90.-C90.0-MeSHMultiple MyelomaPlasmacytomaSequenceLYRA: DRTM1800/BORT1.5/CYCL300/DEXA(20/20), MM, C1-2 (PID1941) -|- C3-6 (PID1942) -|- C7-8 (PID1943) -|- Maint. (PID1944)ChemotherapyChemo-substanceBortezomibCyclophosphamideDaratumumabDexamethasoneChemo-substanceBortezomibCyclophosphamideDaratumumabDexamethasoneChemo-substanceBortezomibCyclophosphamideDaratumumabDexamethasoneChemo-substanceBortezomibCyclophosphamideDaratumumabDexamethasoneNo. Substances4 RadiotherapySupportive therapySupportive substanceAciclovirDexamethasoneDimetindenGranisetronMontelukastParacetamolSupportive substanceAciclovirDexamethasoneDimetindenGranisetronMontelukastParacetamolSupportive substanceAciclovirDexamethasoneDimetindenGranisetronMontelukastParacetamolSupportive substanceAciclovirDexamethasoneDimetindenGranisetronMontelukastParacetamolNo. Substances56Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseInductionTherapy intentiondisease controlRisksConstipationDiarrheaDyspneaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)HyperhidrosisMyalgiasNeutropeniaPainPyrexiaUpper Respiratory Tract Infection only studiesPublicationAuthorYimer HDiseaseMultiples Myelom, neu diagnostiziert oder rezidiviert, ECOG 0-2OriginTexas Oncology-Tyler, US Oncology Research, Tyler, USA, LYRA studyProtocols in Revision 2 protocols foundProtocols under revision.Daratumumab 1800 / Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1-2 (PID1941)Daratumumab 1800 / Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone (20/20), Multiple Myeloma, Cycle 3-6 (PID1942)